Celsion Corporation’s Global Phase III ThermoDox(R) Trial Expands to Malaysia and the Philippines

COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation (NASDAQ: CLSN) announced today that it has received approval from the regulatory agencies in the Philippines and Malaysia for its Pivotal Phase III primary liver cancer Clinical Trial Application.